

**NOTICE OF INTENT TO QUALIFY FOR FILING A PROSPECTUS UNDER
NATIONAL INSTRUMENT 44-101 FOR DISTRIBUTION OF SECURITIES BY MEANS
OF A SHORT FORM PROSPECTUS (“NI 44-101”)**

INNOCAN PHARMA CORPORATION

Date: April 13, 2022

Alberta Securities Commission (Principal Regulator)
British Columbia Securities Commission
Ontario Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
Manitoba Securities Commission
Financial and Consumer Services Commission of New Brunswick
Nova Scotia Securities Commission
Office of the Superintendent of Securities, Prince Edward Island
Office of the Superintendent of Securities Service Newfoundland and Labrador

Dear Sirs:

Re: Notice of Intent under NI 44-101

InnoCan Pharma Corporation (the “**Issuer**”) intends to be qualified to file a short form prospectus under NI 44- 101. The issuer acknowledges that it must satisfy all applicable qualification criteria prior to filing a preliminary short form prospectus. This notice does not evidence the Issuer's intent to file a short form prospectus, to enter into any particular financing or transaction or to become a reporting issuer in any jurisdiction. This notice will remain in effect until withdrawn by the Issuer.

Yours truly,

INNOCAN PHARMA CORPORATION

“Iris Bincovich”

Name: Iris Bincovich
Title: Chief Executive Officer